These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes. Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862 [TBL] [Abstract][Full Text] [Related]
29. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G; Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353 [TBL] [Abstract][Full Text] [Related]
30. Role of abciximab in the treatment of coronary artery disease. Gabriel HM; Oliveira EI Expert Opin Biol Ther; 2006 Sep; 6(9):935-42. PubMed ID: 16918260 [TBL] [Abstract][Full Text] [Related]
31. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol; 1998 Dec; 32(7):2003-10. PubMed ID: 9857885 [TBL] [Abstract][Full Text] [Related]
32. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950 [TBL] [Abstract][Full Text] [Related]
33. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy. Juran NB Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235 [TBL] [Abstract][Full Text] [Related]
34. GP IIb/IIIa inhibitors for STEMI: still the gold standard or an old survivor? Musumeci G; Baroni M; Rossini R Curr Vasc Pharmacol; 2012 Jul; 10(4):443-7. PubMed ID: 22339252 [TBL] [Abstract][Full Text] [Related]
35. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use. Pang JT; Fort S; Della Siega A; Cohen EA J Card Surg; 2002; 17(5):425-31. PubMed ID: 12630543 [TBL] [Abstract][Full Text] [Related]
36. IIb's are not IIb's. Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177 [TBL] [Abstract][Full Text] [Related]
37. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P; Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315 [TBL] [Abstract][Full Text] [Related]
38. Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis. Di Pasquale P; Cannizzaro S; Scalzo S; Maringhini G; Vitrano GM; Giubilato A; Giambanco F; Sarullo FM; Paterna S Int J Cardiol; 2003 Dec; 92(2-3):265-70. PubMed ID: 14659863 [TBL] [Abstract][Full Text] [Related]
39. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720 [TBL] [Abstract][Full Text] [Related]
40. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]